Theravance Biopharma Inc (TBPH)

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria. Its product candidates include TD-1792 that has completed Phase III clinical trials for the treatment of skin and soft tissues infections; Revefenacin (TD-4208), a long-acting muscarinic antagonist, which has completed Phase III clinical studies for chronic obstructive pulmonary disease (COPD); and Velusetrag (TD-5108), an oral and investigational medicine that has completed Phase IIb studies for gastrointestinal motility disorders. The company's product candidates also comprise TD-8954, a selective 5-HT4 receptor agonist for treating gastrointestinal motility disorders; TD-1473, a pan-Janus kinase inhibitor, which has completed Phase Ib clinical study for ulcerative colitis; TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor that has completed Phase II study for neurogenic orthostatic hypotension; and TD-0714 and TD-1439 Neprilysin inhibitors, which have completed Phase I clinical studies for heart failure and chronic kidney disease. In addition, it focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium bromide, and vilanterol for the treatment of COPD and asthma; the inhaled bifunctional muscarinic antagonist-beta2 agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.